Corbus Pharmaceuticals (CRBP) - Quarterly EPS earnings growth

Official company branding of Corbus Pharmaceuticals Holdings (CRBP)

The quarterly EPS growth rate reflects the impact of global liquidity shifts, with the value recorded at 4.60. Geopolitical tensions and sanctions are currently hindering the logistics of testing reagents. The prospects for Corbus Pharmaceuticals (CRBP) depend on the efficacy of ADC drugs against tumors. The absence of commercial products leaves the company entirely dependent on the inflow of external investment capital.

Corbus Pharmaceuticals Holdings (CRBP) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Corbus Pharmaceuticals

- market value and analyst target forecast:
Fundamental company analysis:corbuspharma.com, CRBP
Manufactured product of Corbus Pharmaceuticals, Inc.

Finding a balance between asset quality and market value requires an analysis of profit dynamics. This indicator recalculates quarterly EPS growth on a daily basis, eliminating information gaps between official reports. For Corbus Pharmaceuticals (CRBP), such a metric reflects the financial efficiency of developing selective ADC drugs. It is critical for investors to monitor the risk of slowing growth rates via the quarterly earnings per share chart.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc